Email this article Klinicheskiy opyt ispol'zovaniya antiemetika kitrila v onkologii
- Authors: Borisov VI1
-
Affiliations:
- Онкологический клинический диспансер
- Issue: Vol 1, No 2 (1999)
- Pages: 57-60
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/26350
- ID: 26350
Cite item
Full Text
Abstract
Китрил является высокоэффективным препаратом для профилактики тошноты и рвоты у больных, получающих как высокоэметогенную, так и среднеэметогенную химиотерапию. Кроме того, высокий процент полного купирования тошноты и рвоты достигается как при внутривенном введении, так и при приеме китрила внутрь; это значительно облегчает лечение, улучшает качество жизни больных, что подтверждают сами пациенты.
Full Text
##article.viewOnOriginalSite##References
- М.Л. Гершанович, И.А. Береснева. Возможности применения гранисетрона (китрила) для предупреждения рвоты и тошноты, вызванные цитостатиками. Вопросы онкологии, 1998; 44(2): 225-8.
- Mitchelson F. Pharmacological agents affecting emesis. A review Drugs, 1992; 43:295- 315.
- М.Р.Личиницер, А.В. Кирсанов. Применение противорвотных препаратов при хи миотерапии злокачественных опухолей. Клиническая фармакология и терапия, 1996; 5(4): 74-6.
- Miner D., Sanger G . Inhibition of cisplatin - induced vomiting by selective 5 - hydroxytript - amine M-receptor antagonism. Brit J. Pharmacol, 1986; 88: 497-9-
- Bruijn K. Tropisentron A review of the clini¬ cal experience. Drugs, 1992; 43, (Suppl3): 11- 22.
- Van Wihngaarden J., Tulp M., Sondijn W. The concept of selectivity in 5-HT receptor research. Eur. f. Pharmacol, 1990; 188:301-12.
- Andrews P. The pharmacological profile of granisetron (Kytril). Semin. O ncol, 1994; 21:3- 9.
- Perez E., Navari R., Kaplan H. et al Efficacy and safety of different dosses of granisetron for the prophylaxis of cisplatin - induced emesis. Supportive care - C ancer, 1997; 5(1'): 31-7.
- Ritter H, Gralla R., Hall S. et al. Efficacy of intravenous granisetron to control nausea and vomiting during multiple cycles of cisplatin - based chemotherapy. Cancer - Iuvest, 1998; 16(2): 87-93.
- Tzekova V., Velikova M., Koynov K. Granisetron in repeated cycles of chemotherapi with platinum. Neoplasma, 1998; 45(1): 46-9.
- Sismondi P., Danese S., Giardina G . et al. Antiemetic efficacy of granisetron in patients with gynecological malignancies Anti-C ancer- Drugs, 1997; 8(3): 225-30.
- Perez E., fembersky B., Kay win P. et al. Comparable safety and antiemetic efficacy of brief (30-Second bolus) intravenous granisetron infusion and standard (15-minute) intravenous ondasetron infusion in breast cancer patients receving moderately emetogenic chemotherapy Cancer-J.-Sci-Am., 1998; 4(1): 52-8.
- Koeller f, Takemoto M., C onner C . et al. Clinical outcomes of ondasetron and granisetron in chemoindused emesis in every day practice. Proc.-Annu.-Meet-Am.-Soc.-Clin. Oncol, 1997; 16.-A249
- - Carmichael J., Keizer H, C upissol D. et al. Use of granisetron in patients refractory to previons treatment with antiemetic. Anti-Cancer- Drugs, 1998; 9(5): 381-5.
- Kirchner V., Aapro M., Terry J. et al. A double - blind crossover study comparing prophylactic intravenous granisetron alone or in combination with dexamethasone as antiemetic treatment in controlling nause and vomiting associated with chemotherapy. Eur. f. C ancer, 1997; 33(10): 1605-10.
- Narusef, Minato K, Tsuchiya S. et al. Granisetron plus methylprednisolone versus granisetronalone in prevention of emesis associated with cisplatin - containing chemotherapies. Cancer, 1998; 11(2): 82-5-
- Martoni A, Piana E., Strocchi E. et al. Comparative crossover trial of two intravenous doses of granisetron (1 mg vs 3 mg) + dexamethasone in the prevention of acute cisplatinum - indused emesiss. Anticancer Res., 1998; 18(4): 2799-803.
- Handbergf, Wessel V., Larsenf. et al. Randomized, double - blind comparison of granisetron versus granisetron plus prednisolone as antiemetic prophylactic during multiple - day cisplatin - based chemotherapy. Support-Care-Cancer. 1998; 6(1): 63-7-
- Clark C., Abel S., Dempsey C et al. A cost analysis of ondasetron and granisetron in the management of chemotherapy - induced nausea and vomiting. Hosp.-Pharm., 1998; 33(2): 198-204.
- Gralla R., Navari R., Hesketh P. et al. Single dose oral granisetron has equivalent antiemetic efficacy to itravenous ondasetron for highly emetogenic cisplatin - based chemotherapy, f. Clin. Oncol, 1998; 16(4): 1568-73.
- Perez E., Hesketh P., Sandbach J. et al. Comparison of single - dose oral granisetron versus intravenous ondasetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. A Multicenter, double blind, randomized par ailed study. J. Clin. Oncol, 1998; 16(2): 754-60.
